| 產(chǎn)品名稱 |
Hybridoma 234 s.2a |
| 商品貨號 |
B164812 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Lymphoma |
| Applications |
The antibody reacts preferentially with canine monocytes, but also reacts with canine lymphocytes. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against canine lymphoma cells |
| Cellular Products |
immunoglobulin; monoclonal antibody; against canine lymphoma cells |
| Comments |
Animals were immunized with canine lymphoma cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts preferentially with canine monocytes, but also reacts with canine lymphocytes. It does not cross-react with human cells. This is an IgG2a switch variant of Hybridoma 234 (see ATCC HB-8402). |
| Complete Growth Medium |
Culture Medium: Iscove's modified Dulbecco's medium, 90%; fetal bovine serum,
10%. |
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation |
fetal bovine serum, 95%; DMSO, 5% |
| Isotype |
IgG2a |
| Name of Depositor |
Wistar Institute |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Steplewski Z, Jeglum KA. Monoclonal antibodies against lymphoma-associated antigens, hybrid cell lines producing these antibodies. US Patent 5,169,775 dated Dec 8 1992
|
